| Adamas Pharmaceuticals focuses on time-dependent medicines to enhance the daily living experience of those affected by entral nervous system disorders. Co.'s portfolio includes: GOCOVRI (amantadine) extended-release capsules is for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; and Potential Additional Indications for GOCOVRI (amantadine) Extended Release Capsule (ADS-5102 ), which is in development for the treatment of walking impairment in patients with multiple sclerosis. ADS-5102 is also in research and potential development for additional indications. The ADMS YTD return is shown above.
The YTD Return on the ADMS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ADMS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADMS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.